Active	Status	Sponsor type	Region	Phase	Filter
13 Active 3 Inactive 16 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

13 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Castelnovo, Giovanni
NCT04265209 / 2019-000247-27: [18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor	Recruiting	3	152	Europe	SPECT, PET	Zionexa	Parkinson Disease, Essential Tremor	09/24	12/24
EARLY-PUMP, NCT02864004: Apomorphine Pump in Early Stage of Parkinson's Disease	Active, not recruiting	3	134	Europe	Apomorphine, Apokinon, Best Medical Treatment	Rennes University Hospital	Parkinson's Disease	12/23	01/25
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations	Completed	3	507	Europe, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	Cerevel Therapeutics, LLC	Parkinson Disease	01/24	02/24
TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)	Completed	3	522	Europe, Canada, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	Cerevel Therapeutics, LLC	Parkinson Disease	06/24	06/24
CONSONANCE EXT, NCT05210621: LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB	Active, not recruiting	3	72	Europe	Ocrelizumab	Centre Hospitalier Universitaire de Nice	Multiple Sclerosis	02/26	02/29
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy	Active, not recruiting	2/3	110	Europe, US	AMX0035, Placebo	Amylyx Pharmaceuticals Inc.	Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism	04/26	11/29
PROSPER, NCT06355531: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)	Recruiting	2	220	Europe, US	FNP-223, Placebo	Ferrer Internacional S.A.	Progressive Supranuclear Palsy	11/26	11/26
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD	Active, not recruiting	2	237	Europe, Canada, US	BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo	Bial R&D Investments, S.A.	Parkinson's Disease	03/26	07/26
NCT01823354: Executive Dysfunction in Restless Legs Syndrome: Clinical Correlates and Outcome After Therapeutic Management	Recruiting	N/A	176	Europe	Polysomnography, Clinical Scales, Assessment of executive functions, Medical consultation	University Hospital, Montpellier	Restless Legs Syndrome	05/26	05/26
AGAPO, NCT03693872: Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals	Completed	N/A	43	Europe	Apomorphine, APO, Dopaminergic Agonist + Apomorphine, AGAPO	Rennes University Hospital	Parkinson Disease	06/22	06/22
SODIPARK, NCT06155942: Early Biomarkers of Neurodegeneration in Parkinsonian Syndromes	Not yet recruiting	N/A	63	Europe	7 Tesla MRI, Questionnaires	Assistance Publique Hopitaux De Marseille	Parkinson Disease, Progressive Supranuclear Palsy	01/26	01/28
ALPHA-SEP, NCT05439902: Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women	Recruiting	N/A	60	Europe	Tamsulosin, Placebo	Centre Hospitalier Universitaire de Nīmes	Multiple Sclerosis, Dysuria, Lower Urinary Tract Symptoms, Voiding Dysfunction, Urinary Retention	03/26	03/26
SNP, NCT05198661: Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis Collection	Recruiting	N/A	3500	Europe	Collection of biological sample with sera, CSF, buffy coat, PBMC, plasma.	Hospices Civils de Lyon	Paraneoplastic Neurological Syndromes or Autoimmune Encephalitis	08/32	08/32